Financial analysts have provided valuable insights into Vir Biotechnology Inc. as of March 15, 2024.
—
The average target price for Vir Biotechnology stands at $29.50, with a high estimate of $110.00 and a low estimate of $9.00. Analysts have collectively rated the stock as a Moderate Buy, predicting a potential upside of 181.81% over the next 12 months.
—
In the past three months, 5 financial analysts have shared varying perspectives on Vir Biotechnology, with target prices ranging from $9.00 to $110.00. The average target price among these analysts is $64.80.
—
Analysts have been active in adjusting their ratings and price targets based on market conditions and company performance. For instance, HC Wainwright & Co. has maintained a Buy rating with a target price of $110.00, while JP Morgan has raised its Neutral rating to $10.00.
—
These insights offer a comprehensive view of financial analysts’ opinions on Vir Biotechnology Inc.’s stock performance and future prospects.
VIR Stock Price Drops 3.93% on March 15, 2024: Investors Await Potential Reversal
On March 15, 2024, VIR stock experienced a decrease in price, closing at $10.52, which was $0.43 lower than the previous market close. This represented a 3.93% drop in the stock price for the day.
Investors and analysts will be closely monitoring VIR stock in the coming days to see if it can reverse its downward trend and regain some positive momentum. It will be important to see if the stock can break above its 200-day moving average and start trading closer to its 52-week high in order to signal a potential turnaround in its performance.
Virgin Galactic Holdings Inc. (VIR) Financial Performance Update: March 15, 2024
On March 15, 2024, Virgin Galactic Holdings Inc. (VIR) experienced significant fluctuations in its financial performance compared to the previous year and quarter. According to data from CNN Money, the company reported a total revenue of $86.18 million for the past year, which represents a decrease of 94.67% compared to the previous year. However, the total revenue for the last quarter was $16.79 million, showing a substantial increase of 536.11% since the previous quarter.
In terms of net income, Virgin Galactic reported a net loss of -$615.06 million for the past year, marking a decrease of 219.24% compared to the previous year. The net loss for the last quarter was -$115.97 million, which remained unchanged from the previous quarter.
Earnings per share (EPS) also saw some significant changes for Virgin Galactic. The EPS for the past year was reported as -$4.59, representing a decrease of 219.84% compared to the previous year. However, the EPS for the last quarter was -$0.86, showing an increase of 29.2% since the previous quarter.
Overall, Virgin Galactic’s financial performance on March 15, 2024, reflected a mixed picture of significant decreases in total revenue, net income, and EPS compared to the previous year, but with some positive growth in revenue and EPS since the previous quarter. Investors and analysts may be closely monitoring these fluctuations to assess the company’s financial health and future prospects in the market.
